Immuno-oncology 08/01/2017 Interview: Research Strategies and New Clinical Trial Methodologies... Professor Dolores Schendel joined Medigene as Chief Scientific Officer in 2014 with the acquisition of Trianta Immunotherapies (now Medigene...
Immuno-oncology 08/01/2017 Interview: Collaborations and Combinations with Donnie McGrath,... Donnie McGrath is Vice President, Head of Global search and evaluation in worldwide pharmaceutical finance at Bristol-Myers Squibb. He has been...
Immuno-oncology 08/01/2017 Interview: Harnessing the Power of the Innate Immune System Using... Dr. Klingemann is currently VP of research and development at NantKwest (Nasdaq: NK), the company he founded in 2002 as Zellerx based on the core...
Immuno-oncology 08/01/2017 Five Challenges on the Road to Market Authorisation for Genetically... The reported powerful efficacy immunotherapies using genetically-modified effector cells has the potential to profoundly change the treatment of...
Cell and Gene Therapy 08/01/2017 Interview: a regulator's view on GMO-classified therapeutics... DR. GALLI GAINED A UNIVERSITY DEGREE IN BIOLOGICAL SCIENCES IN 1976 AND A PH.D. IN MOLECULAR MEDICINE IN 1988. CURRENTLY, SHE IS THE IN-STAFF...
Cell and Gene Therapy 08/01/2017 Interview: market authorisation, HTA involvement in early drug... Dr Leeza Osipenko is Associate Director of NICE and works closely with EMA, MHRA, European HTA agencies and EUNETHTA. She chairs most of the...
Immuno-oncology 08/01/2017 Interview: Aiden Courtney, CEO, Roslin Cells Aiden Courtney is CEO of Roslin Cells Ltd. He is an experienced commercial/operational senior executive of early-stage technology and property...
Investment for Advanced Therapies 08/01/2017 Interview: The European Financing Environment and Wales as an... Ajan Reginald is a co-founder of Celixir alongside Professor Sir Martin Evans. Ajan previously served as the global head of emerging technologies...
Immuno-oncology 08/01/2017 Interview: Peregrine CEO Talks Big Pharma Partnerships and... Steve King was appointed President and CEO of Peregrine Pharmaceuticals in March 2003 and has led the company into three phase II clinical programs...
